Reference is made to that certain Series D Preferred Stock Purchase Agreement (the Purchase Agreement), dated as of the date hereof, by and among Finch Therapeutics Group, Inc., a Delaware corporation (the Company), and the purchasers listed on Exhibit A thereto. Capitalized terms used herein without definition shall have the respective meanings ascribed to them in the Purchase Agreement. If the undersigned is included on ExhibitA to the Purchase Agreement, the undersigned agrees to purchase, and the Company agrees to sell and issue to the undersigned the number of shares of Series D Preferred Stock listed on ExhibitA to the Purchase Agreement, at the purchase price referenced in Section1.l{b) of the Purchase Agreement {the Purchase Price), effective as of the date thereof, by execution and delivery of this Omnibus Counterpart Signature Page. The undersigned hereby agrees that, from and after the date thereof, subject to the Purchase Price being paid to the Company, the undersigned is a Purchaser under the Purchase Agreement. If the undersigned is listed on Schedule A of (i)the Third Amended and Restated Right of First Refusal and Co-Sale Agreement (the ROFR), (ii) the Third Amended and Restated Stockholders Agreement (the SHA) and (iii)the Third Amended and Restated Voting Agreement {the VA), the undersigned hereby acknowledges and agrees (A)to the amendment and . restatement of the SHA, VA and ROFR {collectively, the Investor Agreements) (if a party to the corresponding prior agreements before their amendment and restatement), and (B)that the undersigned is a Stockholder under each of the Investor Agreements and is entitled to all of the benefits under, and subject to all of the obligations, restrictions and limitations set forth in, the Investor Agreements that are applicable to the Stockholders. This Omnibus Counterpart Signature Page constitutes a counterpart signature page to each of the Investor Agreements, in the case of the Stockholders, and the Purchase Agreement, in the case of the Purchasers.